Health Bulletin 26/October/2023

Published On 2023-10-26 11:28 GMT   |   Update On 2023-10-26 11:31 GMT

Here are the top health stories for the day:Upper age limit to appoint Senior Resident in PGI Chandigarh increased from 40 to 45 yearsIntroducing a major change, the Postgraduate Institute of Medical Education and Research (PGIMER) has given its permission to modify the upper age limit to appoint senior residents.The institute has now increased the upper age limit from 40 to 45 years. This...

Login or Register to read the full article

Here are the top health stories for the day:

Upper age limit to appoint Senior Resident in PGI Chandigarh increased from 40 to 45 years

Introducing a major change, the Postgraduate Institute of Medical Education and Research (PGIMER) has given its permission to modify the upper age limit to appoint senior residents.

The institute has now increased the upper age limit from 40 to 45 years. This comes as a result of a series of orders and directives issued by the Central Government.

Senior Resident-ship (SRship) is a necessary entry point to medical academics in India. Back in the year 2019, the Union Ministry of Health and Family Welfare extended the age limit to appoint senior residents from 37 years to 40 years.

For more details, check out the link given below:

Upper Age Limit To Appoint Senior Resident In PGI Chandigarh Increased From 40 To 45 Years


"Anguished over state of affairs in Indian Orthopaedic Association", Delhi HC appoints former judge as administrator

The Delhi High Court has expressed anguish at the state of affairs in the Indian Orthopaedic Association (IOA) and appointed its former judge Justice J R Midha as its 'Administrator'.

In an order passed on a lawsuit by some doctors about "serious irregularities" in the conduct of elections to the medical body in November 2020, the court said as the Administrator, Justice Midha, shall conduct the affairs of the IOA till the executive committee is reconstituted pursuant to the elections slated to be held in November 2023.

For more details, check out the link given below:

"Anguished Over State Of Affairs In Indian Orthopaedic Association", Delhi HC Appoints Former Judge As Administrator


Cervical cancer treatment hailed as most ‘remarkable’ breakthrough in 20 years, say scientists

In a groundbreaking development, the INTERLACE phase III trial, sponsored by Cancer Research UK and conducted by researchers from UCL and UCLH, has unveiled promising results for the treatment of locally advanced cervical cancer. The study, spanning a decade and involving 500 patients across multiple countries, revealed that a brief course of induction chemotherapy (IC) followed by standard chemoradiation (CRT) reduced the risk of death or cancer recurrence by 35%.
Notably, patients who received IC followed by CRT exhibited a five-year survival rate of 80%, with 73% remaining free from cancer relapse, compared to 72% survival and 64% relapse-free rates in the group receiving standard CRT alone. A key advantage of this approach is the affordability and accessibility of the drugs employed in IC, carboplatin and paclitaxel, which are already approved and widely available.


WHO's move for regulation of AI in healthcare highlights risks: Report

The World Health Organization's (WHO) recent considerations for the regulation of artificial intelligence (AI) in healthcare, highlights the potential challenges associated with using AI tools in the sector, according to a report on Wednesday.

The WHO regulatory considerations touch on the importance of establishing safety and effectiveness in AI tools, making systems available to those who need them, and fostering dialogue among those who develop and use AI tools.

For more details, check out the link given below:

WHO's Move For Regulation Of AI In Healthcare Highlights Risks: Report

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Health Bulletin 16/ May/ 2024
Health Bulletin 15/ May/ 2024
Medical Bulletin 15/ May/ 2024
Health Bulletin 14/ May/ 2024
Health Bulletin 13/ May/ 2024
Health Bulletin 11/ May/ 2024
Health bulletin 10/ May/ 2024
Health Bulletin 09/ May/ 2024